HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects.

AbstractOBJECTIVE:
PREDICTIVE (Predictable Results and Experience in Diabetes through Intensification and Control to Target: an International Variability Evaluation) is a large, multinational, open-label, prospective, observational study addressed to assess the efficacy and safety of insulin detemir in clinical practice. This paper reports 26 weeks of follow-up data, from 1298 type 2 diabetes patients from Italy.
RESEARCH DESIGN AND METHODS:
In this observational study, the primary end point was the incidence of serious adverse drug reactions (SADRs), including major hypoglycemia. Secondary end points were: hemoglobin A1c (HbA1c), mean self-monitored fasting glucose, within-patient fasting glucose variability and body weight change.
RESULTS:
Insulin detemir significantly improved glycemic control, with a decrease in mean HbA1c, fasting glucose and within-patient fasting glucose variability. Interestingly, the improvements in glycemic control occurred in association with a small, but significant reduction in weight. The safety results of this study showed that 26 weeks of treatment with insulin detemir was associated with a very low rate of SADRs (only 14 events), which mainly consisted of hypoglycemia (78%, of which 42% were major hypoglycemia).
CONCLUSIONS:
Insulin detemir improves glycemic control, with low risk of hypoglycemia, no weight gain and an excellent safety profile; these data support the overall findings of PREDICTIVE.
AuthorsGabriele Perriello, Salvatore Caputo, Giovanni De Pergola, Alberto Di Carlo, Giorgio Grassi, Annunziata Lapolla, Pietro Pata, Sebastiano Bruno Solerte, Francesco Zaccardi
JournalExpert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 12 Issue 16 Pg. 2449-55 (Nov 2011) ISSN: 1744-7666 [Electronic] England
PMID21988213 (Publication Type: Clinical Trial, Clinical Trial, Phase IV, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin, Long-Acting
  • hemoglobin A1c protein, human
  • Insulin Detemir
Topics
  • Adult
  • Aged
  • Blood Glucose Self-Monitoring
  • Body Weight (drug effects)
  • Diabetes Mellitus, Type 2 (blood, drug therapy)
  • Female
  • Glycated Hemoglobin (analysis)
  • Humans
  • Hypoglycemia (blood, prevention & control)
  • Hypoglycemic Agents (adverse effects, therapeutic use)
  • Insulin Detemir
  • Insulin, Long-Acting (adverse effects, therapeutic use)
  • Italy
  • Male
  • Middle Aged
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: